Literature DB >> 1407974

Ocular findings associated with neurofibromatosis type II.

L D Kaye1, A D Rothner, G R Beauchamp, S M Meyers, M L Estes.   

Abstract

BACKGROUND: Neurofibromatosis has been recently acknowledged as consisting of a number of different diseases. Neurofibromatosis (NF) type I and NF type II are the most clearly defined. Type II is characterized by bilateral acoustic neuromas and is rare (its incidence is 1/50,000). The previously reported ocular associations of NF type II are posterior subcapsular cataracts, Lisch nodules, and combined hamartomata of the retinal pigment epithelium and retina. In this study, the authors attempt to define further the ocular manifestations of NF type II.
METHODS: The authors prospectively examined 9 patients who met the diagnostic criteria for NF type II (age, 18 to 38 years; mean, 25 years).
RESULTS: Seven of nine patients had epiretinal membranes in the posterior pole. None of these epiretinal membranes were visually significant. In addition, five patients had central posterior cortical cataracts and five had peripheral wedge-shaped cortical cataracts.
CONCLUSION: The presence of epiretinal membranes in young patients may represent another clinical finding associated with NF type II. Epiretinal membranes, central posterior cataracts, peripheral cortical cataracts, or combined hamartoma of the retinal epithelium and retina in young patients should alert the ophthalmologist to include NF type II in the differential diagnosis in patients with stigmata of NF type II.

Entities:  

Mesh:

Year:  1992        PMID: 1407974     DOI: 10.1016/s0161-6420(92)31789-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

Review 1.  The role of the lens actin cytoskeleton in fiber cell elongation and differentiation.

Authors:  P Vasantha Rao; Rupalatha Maddala
Journal:  Semin Cell Dev Biol       Date:  2006-11-01       Impact factor: 7.727

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 3.  Functions of the intermediate filament cytoskeleton in the eye lens.

Authors:  Shuhua Song; Andrew Landsbury; Ralf Dahm; Yizhi Liu; Qingjiong Zhang; Roy A Quinlan
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

4.  Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases.

Authors:  Lynn J Poole Perry; Frederick A Jakobiec; Fouad R Zakka; Elias Reichel; Martina C Herwig; Arie Perry; Daniel J Brat; Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2012-12-06       Impact factor: 5.258

Review 5.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

6.  Retinal changes associated with neurofibromatosis 2.

Authors:  S M Meyers; F A Gutman; L D Kaye; A D Rothner
Journal:  Trans Am Ophthalmol Soc       Date:  1995

7.  Combined hamartoma of the retina and retinal pigment epithelium associated with neurofibromatosis type-1.

Authors:  R N Vianna; D F Pacheco; M M Vasconcelos; J J de Laey
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

8.  Ocular fundus in neurofibromatosis type 2.

Authors:  K Landau; G M Yaşargil
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

9.  Spectral-domain optical coherence tomography of combined hamartoma of the retina and retinal pigment epithelium in neurofibromatosis.

Authors:  Hae Min Kang; Hyoung Jun Koh; Eun Jee Chung
Journal:  Korean J Ophthalmol       Date:  2012-12-18

10.  Familial bilateral combined hamartoma of retina and retinal pigment epithelium associated with neurofibromatosis 1.

Authors:  Sanaa A Yassin; Elham R Al-Tamimi
Journal:  Saudi J Ophthalmol       Date:  2012-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.